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KAJIAN FARMAKOLOGI DAN FITOKIMIA TERHADAP BIJI 
MAHOGANY 
ABSTRAK 
Swietenia mahagoni yang berasal daripada famili Meliaceae digunakan sebagai ubat-
ubatan tradisional. Setakat ini, tiada laporan atau artikel yang telah diterbitkan 
tentang biji benih S. mahagoni yang berasal dari Malaysia. Oleh kerana itu, kajian ini 
direka bentuk untuk menentukan sifat-sifat farmakologi biji benih S. mahagoni untuk 
analisis agen antimikrob, antioksidan, analgesik dan untuk pemeriksaan tahap 
ketoksikan. Analisis fitokimia menunjukan kandungan alkaloid, terpenoids, 
antrakuinon, cardiac glikosida, saponin, dan minyak-minyak essential sebagai unsur-
unsur aktif utama. Penilaian ketoksikan akut mencit menunjukan bacaan LD50 yang 
lebih dari 5000 mg/kg. Ini bermakna, ekstrak biji benih SMCM berpotensi untuk 
mengandungi bahan terapeutik yang selamat dari sebarang kesan toksik. Kajian telah 
dijalankan untuk mengetahui aktiviti antimikrob ekstrak biji benih SMCM ke atas 
bakteria Gram positif, Gram negative, yis and kulat. Ekstrak ini didapati aktif 
terhadap yis Candida albicans. SMCM biji benih ekstrak mengandungi aktiviti-
aktiviti yang berkesan untuk in vitro dan in vivo aktiviti anti-Candida terhadap C. 
albicans. Seterusnya aktiviti antioksidan dan analgesik telah dikaji dan mendapati 
ekstrak biji benih SMCM mempunyai aktiviti antioksidan yang sederhana. Ekstrak 
biji benih SMCM menunjukan analgesik aktiviti pada dos yang lebih tinggi. SMCM 
ekstrak menunjukan aktiviti anti-Candida yang tinggi. Oleh kerana itu, kajian telah 
dilanjutkan untuk mengenal pasti bahan bioaktif yang mungkin memberi kesan 
aktiviti anti-Candida. Kumpulan bioaktif terpenoid (SM Sp1) didapati berkesan 
terhadap C. albicans dalam kajian bioautografi dengan nilai MIC 150 µg/mL. FTIR 
xxiii 
 
analisis menyokong bahawa SM Sp 1 mempunyai ciri-ciri regangan seperti 
kompound Swietmanin J. Penemuan menunjukkan ekstrak biji benih SMCM 
mempunyai aktiviti anti-Candida yang ketara. Penemuan ini boleh menyumbang ke 
arah pembangunan bidang penggunaan ubat-ubat tradisional berasaskan tumbuhan 
dalam sektor bioteknologi dan industri farmasi di Malaysia. Oleh yang demikian, 
kajian lanjutan dalam pengasingan dan pencirian bahan bioaktif anti-Candida adalah 
disarankan pada masa hadapan. 
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THE PHARMACOLOGY AND PHYTOCHEMISTRY 
STUDY OF MAHOGANY SEEDS 
ABSTRACT 
 
Swietenia mahagoni which belongs to the Meliaceae family has been applied in folk 
medicine. To date there are no report or articles that published on the Malaysian 
origin S. mahagoni seeds. Therefore, this research was designed to investigate the 
pharmacological efficacy of S.mahagoni seeds for phytochemical analysis, 
antimicrobial, antioxidant, analgesic activities and for toxicity screening. The 
phytochemical analysis exhibited the presence of terpenoids, saponins, volatile oils, 
alkaloids, antraquinones, and cardiac glycosides as major active constituents. Acute 
oral toxicity evaluation exhibited the LD50 was relatively greater than 5000 mg/kg. 
This shows that, SMCM seed extract may contain potential therapeutic bioactive 
which is free from toxic effects. Antimicrobial activity of SMCM seed extract 
against Gram positive and Gram-negative bacteria and fungus strains was 
undertaken. The extract was found to be more active against Candida albicans. 
SMCM seed extract is effectively active for in vitro and in vivo anti-Candida activity 
against C. albicans. The SMCM seed extract was evaluated for antioxidant and 
analgesic activities and found to possess moderate antioxidant activity and analgesic 
activity at tested higher dose. SMCM seed extract shows good anti-Candida activity. 
Therefore, further work was undertaken to identify the possible bioactives for the 
anti-Candida activity. A terpenoid bioactive group was found to be active against C. 
albicans in bioautography assay with MIC value of 150 µg/mL. The FTIR analysis 
of SM Sp1 showed almost comparable stretching groups with an identified 
compound Swietmanin J. Our findings showed that, SMCM seed extract possess 
xxv 
 
therapeutic property for anti-Candida activity. These findings could assist the herbal 
drug development in Malaysian biotechnology and pharmaceutical industry. 
Therefore, in future, further works on isolation and characterization of the pure anti-
Candida bioactive are recommended. From the overall findings, the most promising 
activity of the SMCM seed extract was observed in its anti-Candida activity.  
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CHAPTER 1 
INTRODUCION 
Swietenia mahagoni (Linn.) Jacq. (Meliaceae) is a large, deciduous, and 
economically important timber tree, which is native to the West Indies. S. mahagoni 
is one of the most popular traditional medicines in Africa (Abdelgaleil and Aswad, 
2005). Currently large numbers of pharmacological studies have being carried out on 
this plant parts. The chestnut brown colour seeds have also been reported to have 
medicinal value for treatment of cancer, amoebiasis, coughs, chest pains and 
intestinal parasitism (Alrdahe et al., 2010). However, there is lack of scientific 
investigation on S. mahagoni seed extract from Malaysia. Therefore, to explore the 
pharmacology effects of S. mahagoni seeds, a few groups of studies were focused in 
this project.  
At present, there is a dilemma of microbial drug resistance and there is a raise 
of opportunistic infections especially with AIDS patients and individuals on 
immunosuppressive chemotherapy (Stark et al., 2009). Moreover, there are several 
antifungal and antiviral prescriptions, which have limited use due to their toxicity 
effect, while we have yet to find a cure for viral diseases (Pauli, 2006 and Scorzoni et 
al., 2007). Presently human fungal contagion has increased at an alarming rate in the 
last 20 years, mainly among immunocompromised individuals (Perea et al., 2002; 
Scorzoni et al., 2007).  Oral candidiasis is the most widespread opportunistic 
infection associated with 90% of HIV-infected individuals (Torssander et al., 1987; 
Feigal et al., 1991; Patel et al., 2008). Candida albicans is the most recurrent 
etiological agent associated with candidiasis infection. Furthermore, isolates of this 
species from HIV-positive patients are more virulent and genotypically altered than 
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strains from HIV-negative patients (Challacombe et al., 1995; Sweet et al., 1995; 
Patel et al., 2008). With the mounting recognition of herbal remedy as an alternative 
form of health care, the screening of therapeutic plants for bioactive is becoming 
increasingly important (Rabe and Van Staden, 1997; Shai et al., 2008). Therefore, 
anti-Candida activity against Swietenia mahagoni seed extract was mainly given 
importance in this study.  
In addition to emerging problems of drug resistance in infectious diseases, 
multi-factorial diseases due to imbalance of antioxidant system in human body is 
also becoming another major existing crisis (Tiwari, 2004). Reactive oxygen species 
(ROS) formed in vivo are highly reactive and potentially damaging the transient 
chemical species in our body system (Ali et al., 2008). Over-production of this 
reactive species, induced failure in the defense mechanisms and damage to cell  
structures,  DNA,  lipids  and  proteins  (Valko et al., 2006) and increases the risk of 
more than 30 different disease processes in human body (Aruoma, 1998). Currently 
the presences of enzymatic and non-enzymatic antioxidants are possible to reduce the 
risks of chronic diseases and prevent disease progression (Stanner et al., 2004; Ali et 
al., 2008). Many studies have proven that, either by enhancing the body’s natural 
antioxidant defenses or by supplementing with dietary antioxidants, we can 
overcome the effects of ROS. Therefore, major efforts are concentrated towards 
discovering and synthesizing novel antioxidants. Due to this reasons, S. mahagoni 
seed extract was also used to evaluate the property of the antioxidant activity.  
Another foremost cause that leads for the evaluation of analgesic effects on S. 
mahagoni seed extract is to discover an alternative medication for pain emancipation. 
Pain is the most apparent reason for an individual to search for therapeutic attention. 
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Presently the treatment for chronic pain has turned into a major problem due to the 
use of available medications and their undesirable side effects. The side effects of 
currently used pain medications are addiction, tolerance, gastrointestinal effects, and 
abuse (Elisabetsky et al., 1995). There are a lot of up coming literature reports 
regarding the analgesic activity in medicinal plants. Therefore, S. mahagoni seed 
extract was also exploited to discover new analgesic drugs as alternatives to synthetic 
pain relief drugs.  
This search on S. mahagoni seed methanolic extract could also reveal more 
about the pharmacological effects and phytochemistry cores of the seeds and 
simultaneously it would assist for the growth of new herbal drug in the Malaysian 
biotechnology industry.  
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1.1 OBJECTIVES 
The objectives of this the present study is as follows: 
 To conduct phytochemical analysis for major constituents of Swietenia mahagoni 
methanolic crude extract seed extract. 
 To conduct acute oral toxicity study on Swietenia mahagoni methanolic crude 
extract. 
 To evaluate antimicrobial activity on the test samples (methanolic crude extract) 
of Swietenia mahagoni seed  
  To carry out various antioxidant tests on Swietenia mahagoni seeds test samples. 
 To investigate the analgesic property of Swietenia mahagoni crude methanolic 
seed extract. 
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1.2 RESEARCH FLOW 
Swietenia mahagoni seeds were macerated using methanol solvent to obtain 
Swietenia mahagoni crude methanolic (SMCM) extract. This crude extract was 
subjected to a few pharmacological screening using various standard methods (as 
described in Chapter 2: Materials and Methods) for analgesic, antioxidant, and 
antimicrobial activity evaluation. Based on the evaluation, SMCM seed extract 
retained good anti-Candida activity against Candida albicans. Therefore, further 
study was mainly focused on the identification and characterization of the bioactive 
for anti-Candida activity. The research flow for this study is clearly explained in 
Figure 1.1. 
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Figure 1.1: Research flow for the pharmacology and phytochemistry studies of 
Swietenia mahagoni seed extract.  
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CHAPTER TWO 
LITERATURE REVIEW  
2.1 Herbal drug 
Therapeutic plants have been natural resources for the treatment of various 
diseases since ancient times. Medicinal plants would be the paramount resource to 
obtain a variety of drugs according to the World Health Organization (WHO) survey 
(Santos et al., 1995 and Sukanya et al., 2009); reports show that about 80% of 
individuals from developed countries are still accustomed to traditional medicine 
practice. WHO statistic testify that about 20,000 plant species are used as curative 
targets (Gullece et al., 2006; Maregesi et al., 2008) for hundreds of diseases.  
Current surveys estimate that globally 25 % of prescribed drugs are derived 
from plants products and around 121 active compounds are presently in use. Indeed 
11 % of the total 252 drugs in WHO’s essential medicines list are exclusively from 
plant based origin (Rates, 2001). Almost 80 % of the African and Asian populace 
depends on traditional medicine for their primary healthcare (WHO, 2008). 
Mukherjee reported that the indigenous systems of medicine have dominated around 
80% of the rural areas in India (Mukherjee and Wahile, 2006). In general, the 
information above indicates that herbal medicine has been widely used by people 
from all cultures throughout history. Examples of modern clinical medications 
derived from natural products are salicylic acid, a precursor of aspirin is originally 
derived from the white willow bark and meadowsweet plant; Quinine derived from 
cinchona bark actively use in treatment of malaria and vincristine obtained from 
periwinkle is used to treat certain types of cancer (Mukherjee and Wahile, 2006). 
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Searches reveal that, 74 % of pharmacologically active plant derived components 
were discovered after following up on the ethnomedicinal use of the plants (Ncube et 
al., 2007). The growth of pharmaceuticals involves identification of active principles, 
its pharmacological effects, dosage formulations and clinical studies to establish 
safety, efficacy and pharmacokinetic profile of the novel drug (Iwu et al., 1999; 
Ncube et al., 2007). Hence, for the development of herbal drugs from natural 
sources, ethnobotanical and ethnopharmacological research is very essential.  
In ethnobotanical approaches, there is three generation of plant drugs 
according to Iwu et al. (1999) classification. The first generation of herbal drugs is in 
the crude form of plant extract. Several first generation effective medicines used in 
their natural state are such as cinchona, opium, belladonna and aloe (Iwu et al., 
1999). The second generation of plant-based drug emerged after scientific processing 
of the plant extracts to isolate their active constituents.  This generation of herbal 
drugs is pure molecules and the notable examples are quinine from Cinchona, 
reserpine from Rauvolfia, and taxol from Taxus species (Iwu et al., 1999). The third 
generation of phytotherapeutic agent is usually developed based on top-bottom 
approach. It consists of clinical evaluation of the particular drug and followed by 
cytotoxicity, acute and chronic toxicity screening. An acceptable safety index 
substance will only be subjected to detail pharmacological/biochemical studies (Iwu 
et al., 1999).  
Ethnopharmacology is defined as the scientific study on medicinal plants 
which is correlated with ethnic groups, their health and how it is related to their 
physical condition. The ethnopharmacological approach is used to study the 
pharmacopoeias of Traditional Chinese Medicine (TCM), the European 
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pharmacopoeias, or the medicinal plants from traditional ethnic groups. Various 
pharmacological activities including analgesic, antimicrobial, antioxidant, anti-
inflammatory, antidiabetic and other activities were undertaken in laboratory 
conditions.  In a review by Maganha et al. (2010) it is stated that, Hibiscus genus has 
potential bioactive molecules, such as phenolic compounds, triterpene derivatives, 
phytosteroids, with antioxidant, cardioprotective, antihypertensive and 
antiproliferative effects (Maganha et al., 2010).  Lycium barbarum polysaccharide, 
showed antioxidative properties and some interesting pharmacological activities in 
the context of age related diseases such as atherosclerosis and diabetes (Potterat, 
2010). This shows that the development of plant based therapeutic is growing quite 
remarkably. The main core for the usage of herbal medicine is that, it causes fewer 
side effects than pharmaceuticals. Common herbs function physiologically to restore 
balance in the body rather than just to target the symptoms. For this reason, herbs 
often tend to show effects more gradually but the effects derived are more efficient 
than the modern medicines.  
Major pharmaceutical companies and academic researchers are undertaking 
extensive studies on all parts of plant materials. Ordinarily, leaves, fruits, bark, 
flowers, seeds, and roots are essentially targeted for their therapeutic effects. 
Sufficient understandings of the herbal system including biological, chemical, 
genetic and agronomic aspects are required for the formulation of an herbal 
medicine. Bioactive element reliability throughout the development process such as 
extraction, bio-guided assay, purification and shelf life is of utmost importance to 
certify medicinal effectiveness and consumer safety. Generally, various steps are 
involved in the development of an herbal medicine (Figure 2.1) starting from raw 
material collection to the isolation of bioactive compounds (Sahoo et al., 2010). 
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Figure 2.1: Steps involvend in the developmet of a phytomedicine in market (Sahoo 
et al., 2010).  
 
 
 
Collection of Raw Materials
Botanical Identification
Extraction Process
Grinding / Powdering
Purification
Isolation of Active Compounds
Pharmacological Activity Screening 
Qualitative Analysis 
(Chromatographic Techniques) 
Fraction and Toxicity Evaluation
 
 
11
2.2 Herbal medicine in Malaysia 
Nature has blessed Malaysia with a great quantity and quality of varied 
medicinal plants.  At present, Malaysia has been rated the world’s 12th mega 
biodiversity rich with its flora and fauna (Institute for Medical Research, 2002 and 
Ang, 2004). Various medicinal plants have been used for years in the daily life of 
Malaysians. Numerous studies have been carried out to survey the practices of 
traditional medicines in villages such as Gemenceh, Negeri Sembilan and Machang, 
Kelantan (Ong and Nordiana, 1999).   
In Malaysia, commercial traditional herbal medicines, popularly known as 
“jamu” and “makjun”, are readily available and consumed regularly (1–3 times 
daily) to promote health (Ali et al., 2005). In a survey, Aziz and Tey (2009) state 
that, one in three Malaysians adults in urban areas use herbal medicines daily. A few 
major factors which influence the use of herbal medicines are gender, ethnicity, age, 
and perceived health status (Aziz and Tey, 2009). Aziz and Tey (2009) found that, 
Malays rank first in the use of traditional herbal medicines as compared to Chinese 
and Indians. Malays are 6 times more likely to use herbal medicines than Indian and 
1.5 times higher than the Chinese (Aziz and Tey, 2009).  
As such, the Drug Control Authority (DCA) of Malaysia implemented the 
Phase Three registration of traditional medicines on 1 January 1992. This Act 
necessitates for special emphasis on the quality, efficacy and safety in all 
pharmaceutical dosage in any form of traditional medicine preparations (National 
Pharmaceutical Control Bureau, 1993 and 1999; Ang, 2004).  
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A survey shows that, in 1997, Malaysian consumers spent about six times 
more on herbal product than the United States consumers per capita, with their 
respective populations of 22 and 273 milions (Malaysian National News Agency, 
2006; Aziz and Tey, 2009). According to Frost and Sullivan market research report, 
the Malaysian pharmaceutical industry was valued at approximately  USD  1.03  
billion  in  2007  and  is  estimated  to reach USD 1.8 billion by 2013 (Tham and 
Yahya, 2009; Chua et al., 2010). As to date,  there  are  234  pharmaceutical  
companies that  are  registered  with  the  DCA  with  67  companies involved in the 
production of modern medicines while the remaining 167 companies are local 
traditional and herbal medicine manufacturers (Malaysian Industrial Development 
Authority, 2009; Chua et al., 2010).  
The current situation of herbal medicine practices and development of the 
pharmaceutical industry in Malaysia highlights the importance of herbal drug 
discovery and development. With this in view, a traditionally used plant (Swietenia 
mahagoni) was selected to scientifically investigate and to determine the 
pharmacological effects of the plant in this thesis. The review of the plant species is 
described below.  
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2.3 Swietenia mahagoni  
2.3.1 General view of plant 
Swietenia mahagoni Jacq. is clustered under the Meliaceae family. It is a 
large, deciduous, and economically important timber tree which is native to the West 
Indies (Mulholland et al., 1992; Chen et al., 1997; Chen et al., 2007). The common 
names for S. mahagoni (SM) are small leaved, West Indian, Spanish or Cuban 
mahogany, caoba, Madeira, coabilla, caoba dominicana, and acajou. The S. 
mahagoni Jacq. synonyms are Swietenia mahogoni (L.) Lam., Swietenia fabrilis 
Salisbury, Cedrus mahogany (L.) Miller.  
S. mahagoni is a humid zone species, with natural distribution in the 
Caribbean region (South Florida, Bahamas, Antilles, Haiti and Jamaica) (Schmidt 
and Joker, 2000). The species is over exploited in much of its natural area of 
distribution and has been registered on CITES Appendix II (1992) as an endangered 
species. It has been extensively planted in southern Asia (India, Sri Lanka, 
Bangladesh) and in the Pacific (Malaysia, Philippines, Indonesia and Fiji), and has 
been introduced for cultivation in West Africa (Schmidt and Joker, 2000).  
 2.3.2 Botanical description of the plant 
S. mahagoni is an evergreen to semi-evergreen tree and can grow up to 30-35 
m. The bark of this tree is grey in colour and smooth when it is young and turns to 
dark brown, ridged and flaky when mature. The leaves are clustered, glabrous, 12-15 
cm long and paripinnately compound with 2-4 pairs of leaflets. The leaflets are 
ovate-lanceolate shape, 5 to 6 cm long, 2 to 3 cm wide, dark green and glabrous, 
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while the flowers are unisexual, small and white to greenish in colour and in the form 
of 8 to 15 cm long slender panicles (Schmidt and Joker, 2000).  
 
Figure 2.2: Swietenia mahagoni leaves and fruits.   
2.3.3 Flowering and fruiting habit of Swietenia mahagoni  
Mahoganies usually have ordinary annual flowering and begin bearing fruits 
10 to 15 years of age. The S. mahagoni flowers are unisexual and the trees are 
monoecious. In general, the pollination occurs by insects. Usually only one flower of 
the inflorescence develops into a fruit with the other flowers being aborted, even 
though fertilization has taken place in the particular flowers. Generally, development 
of the flower into a mature fruit will take from 8 to 10 months. The flowering 
sessions vary according to the climate of the growth environment i.e. in a 
geographical site flowering usually takes place shortly before the rainy season. Based 
2cm 
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on the observation, S. mahagoni flowering in Malaysia (Penang) occurs between 
April and July and the fruits mature between December and February.  
 
Figure 2.3: Swietenia mahagoni flower.   
2.3.4 Fruit and seed description of Swietenia mahagoni 
The fruits are erect, 5 to 10 cm length, 3 to 6 cm in diameter, oblong, and 
usually are in 5-celled dehiscent capsules. The valves are thick and woody with a 
coriaceous surface when mature. Normally, the outer valves are 4 to 5 cm thick and 
the inner valves will be very thin (Schmidt and Joker, 2000). The fruit splits open 
from the base or simultaneously from the base and the apex when it is mature. The 
centre of the fruit has a thick, woody, and 5-angled columella part which extends to 
the apex. The seeds hang pendulous by their wing in the woody part. There are 
usually about 35 to 45 seeds per fruit (Schmidt and Joker, 2000). 
2cm 
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The seeds are chestnut brown in colour, 4 to 5 cm long, compressed, crested 
and extended into a wing at the attachment end. The cotyledons are fused in the 
upper two thirds along the axial surface. In general, the seeds are dispersed by wind 
(Schmidt and Joker, 2000).  
 
Figure 2.4: Fruit and seed within the wing.  
 
Figure 2.5: Seed of Swietenia mahagoni.  
Encapsulated seed in wing 
Pericarp  
2cm 
2cm 
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2.3.5 General usage of Swietenia mahagoni 
S. mahagoni has the potential for huge scale timber production plantations, 
especially in dry areas, due to its excellent timber quality. It is also used in 
agroforestry, for soil improvement and as an ornamental plant (Schmidt and Joker, 
2000). S. mahagoni is closely related to the African genus Khaya and it is one of the 
most popular traditional medicinal plants in Africa. 
2.3.6 Pharmacology effects of Swietenia mahagoni 
S. mahagoni seeds have been applied as a folk medicine for the treatment of 
hypertension, diabetes, and malaria, while the decocted bark has been used as a 
febrifuge (Darzeil, 1937; Mulholland et al., 2000; Chen et al., 2007). The decocted 
bark of S. mahagoni is used as febrifuge which can be associated with its use as an 
antimalarial drug (Darzeil, 1937). S. mahagoni has also been used as an antipyretic, 
tonic, and astringent (Anon, 1986; Gautam et al., 2007) and was used as folklore 
medicine in Puerto Rico (Antoun et al., 2001; Gautam et al., 2007). S. mahagoni has 
been reported to have medicinal uses, such as for the treatment of cancer, 
amoebiasis, chest pains and intestinal parasitism (Bascal et al., 1997). The 
biologically active ingredients, tetranortriterpenoids and fatty acids are considered to 
be responsible for these therapeutic effects (Bascal et al., 1997). In addition, 6-
acetylswietenine and 6-acetyl-3-tigloyl-swietenolide from S. mahagoni has been 
shown to effectively reduce the number of rust pustules on detached groundnut 
leaves (Govindachari et al., 1999a). Ether extract from the stem bark of S. mahagoni 
(studies from Alexandria, Egypt) showed potent activity against Spodoptera insects 
(Saad et al., 2003). Whereas, Swietenialides A, B, and C; swietenialides D and E and 
mexicanolide, 2-hydroxyswietemin showed antifeedant activity against S. littoralis 
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(Boisduval) (Saad et al., 2003). The bark of S. mahagoni has been used as astringent 
for wounds due to the active tannin substances caused by the rich red colour (Falah et 
al., 2008). The seeds of S. mahagoni have been used for leishmaniasis and as 
abortion medicine by an Amazonian Bolivian ethnic group (Bourdy et al., 2000). The 
seed extract also can be used as a potential agent for diabetes therapy because it 
shows agonistic activity to peroxisome proliferator-activated receptor γ (PPARγ) and 
can ameliorate the blood glucose levels of diabetic db/db mice (Li et al., 2005). To 
support this finding, De, and coworkers found an aqueous-methanolic extract of S. 
mahagoni seed is potential for the correction of diabetes and its related complications 
like oxidative stress and hyperlipidemia (De et al., 2011). Other than these, 
swietemahonin A, D, E, and G and 3-O-acetylswietenol ide and 6-O-acetylswietenol 
ide, from the seeds showed a strong inhibition against platelet-activating factor 
(PAF)-induced aggregation in vitro and in vivo assays (Ekimoto et al., 1991). Recent 
studies in Bangladesh showed that the chloroform extract of the seed and ethyl 
acetate extract of bark both demonstrated good cytotoxic activities. In addition, both 
chloroform and ethyl acetate extracts of the leaf and bark demonstrated a good 
activity against human pathogenic bacteria. The chloroform seed extract exhibited 
antimicrobial activity only against Bacillus megaterium, Salmonella paratypi, 
Shigella dysenteriae, Pseudomonas aeroginosa and S. boydii (Haque et al., 2009). 
The isolated active principle 2-hydroxy-3-O-tigloylswietenolide from the S. 
mahagoni seed shows potent activity against tested multiple-drug-resistant bacterial 
strains (clinical isolates: Streptococcus aureus, Staphylococcus aureus, 
Streptococcus pneumonia, Haemophilus influenzae, Escherichia coli, Klebsiella 
pneumonia, Salmonella typhi, and Salmonella paratyphi) (Rahman et al., 2009).  
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2.3.7 Chemical substances identified from Swietenia mahagoni 
Previous chemical investigations on this West Indies mahogany species from 
a few countries such as India, Indonesia, and Egypt have led to the isolation of more 
than 40 limonoids belonging to the structural types of gendunin, mexicanolide, and 
phragmalin (Mulholland et al., 1992; Saad et al., 2003; Chen et al., 2007). Currently 
two novel limonoids, swiemahogins A and B were isolated from the twigs and leaves 
of S. mahagoni. They are the first examples of andirobin and phragmalin types of 
limonoids from twigs and leaves reported by Chen et al., (2007). Furthermore, a 
tetranortriterpenoid, 6-Desoxyswietenine was also identified by Govindachari et al., 
(1999b). A number of limonoids have also been reported from the genus Swietenia 
(the true mahoganies) with structures assigned on the basis of spectral data (Kadota 
et al., 1990a). Ever  since  two  rings  B,D-seco  limonoids  of methyl  angolensate 
and its 6-hydroxy derivative were isolated by Taylor (1969) many mexicanolide-type 
compounds of rings B,D-seco limonoid having a bicyclo[3,3,1]-ring system such as 
swietenin (Connolly et al., 1965) have been isolated  from S. mahagoni (Kadota et 
al., 1990a). A subsequent study of the leaves, indicates the presence of seven new 
phragmalins possessing an orthoester group at 8,9,30-position (swietephragmins A– 
F and G), together with two new different type rings B,D-seco limonoids (2-
hydroxy-3-O-tigloylswietenolide and deacetylsecomahoganin). Three known 
limonoids [methyl 6-hydroxyangolensate (Adesogan and Taylor, 1968), 
swietemahonin G (Kadota et al., 1990b) and 7-deacetoxy-7-oxogedunin (Kadota et 
al., 1990a) were also isolated from the leaves of S. mahagoni. New compounds from 
the seeds of S. mahagoni, named swietemahonin A, D, E, and G and 3-O-
acetylswietenol ide and 6-O-acetylswietenol ide were isolated by Ekimoto research 
team (Ekimoto et al., 1991). From the seeds of S. mahagoni, 18 tetranortriterpenoids, 
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(five swietenins (B-F), three acylswietenolides, seven swietemahonins (A-G), 
swietemahonolide, mahonin and secomahoganin related to swietenine and 
swietenolide were isolated and identified (Kadota et al., 1990c).  
2.3.8 Conclusion 
This review illustrates that the plant species is widely used traditionally for its 
pharmacological effectiveness. However the scientific investigation of Swietenia 
mahagoni seed in terms of its likely antimicrobial, antioxidant, analgesic activity are 
still lacking in literature. The toxicity aspects of Swietenia mahagoni seed extract yet 
to be reported. These pharmacological findings will assist the herbal drug discovery 
and development in Malaysian pharmaceutical and biotechnology industries.  
2.4 Toxicity  
Practices of traditional medicine vary greatly according to the place and 
influenced by culture, history, personal attitudes and philosophy factors. However, 
there is lack of scientific investigation in the safety and efficacy for the most of 
herbal medicines. Herbal medicines contain bulk of active organic compounds and 
are employed in the treatment of diseases of diverse origins. The practitioners most 
often prepare the medicines with a combination of two or more plant products for the 
treatment of more than one disease condition (Pieme et al., 2006; Ogbonia et al., 
2009).  
Herbal drugs usage are very vast, the doses are not quantified and most 
importantly toxicity of these plants’ drugs are largely unknown (Saad et al., 2006). 
The danger associated with the potential toxicity of such therapy and other herbal 
therapies used over a long period of time demand that the practitioners be kept 
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abreast of the reported incidence of renal and hepatic toxicity resulting from the 
ingestion of medicinal herbs (Tedong et al., 2007; Ogbonia et al., 2009). Although a 
number of scientific researchers have revealed activities of so many plants not many 
people venture into studying toxicity of these plant materials.   
Currently a lot of reports are alarming side effects and toxicity resulting from 
the ingestion of herbal medicines. The standardized extract of Ginkgo biloba has an 
inhibitory action on blood pressure and it may influence cortisol release in response 
to some stress stimuli (Jezova et al., 2002), may cause hemorrhage and hyphema 
(Schneider et al., 2002) and may increase the risk of bleeding or potentiate the 
effects of warfarin therapy (Heck et al., 2000). Plant flavonoids actually have the 
capacity to become carcinogenic at higher levels. High doses of these chemicals also 
carry other health risks including a small but documented risk for a rare form of 
leukemia in young children. Ginseng reinforces warfarin action by heterogeneous 
mechanisms. It should thus not be used in patients on oral anticoagulant and/or 
antiplatelet therapy (Argento et al., 2000) and Ashwagandha is a potential source of 
hypoglycemic, diuretic and hypocholesterolemic agents (Andallu and Radhika, 
2000). The current evidence suggests that oral evening primrose oil does not provide 
clinically significant improvement in persons with atopic dermatitis, and that it is 
also likely ineffective for the treatment of cyclical mastalgia and premenstrual 
syndrome (Bayles and Usatine, 2009) and hepatotoxic reactions have been observed 
after the ingestion of Senna (Stickel et al., 2001) .  
The in vivo toxicity study in animal is more indicative toxicity safety 
markers. Animals’ toxicity tests are conducted prior to human clinical investigation 
as part of non-clinical laboratory tests of pharmaceuticals.  
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2.4.1 Acute oral toxicity in animal models 
 Acute toxicity is usually defined as unfavorable effects occurring within a 
short period of time with administration of a single dose or multiple doses 
substance(s) within 24 hours (Walum, 1998). Toxicity effects generally will be 
classified as any affect that results in functional destruction and/or biochemical 
lesions that may affect the performance of the whole organism or reduce the organ’s 
ability (Rhodes et al., 1993; Walum, 1998). The term acute toxicity is most often 
used in connection to lethality and median lethal dose (LD50) determination.   
 The rationale behind of acute toxicity investigation is to collect 
information on the biologic activity of a tested material and gain insight into its 
mechanism of action. The dosed animal is closely observed during the first 24 hour 
and day by day for as long as two weeks and the behavioral changes are noted. To 
examine the toxic level of the herbal remedies, basic toxicity evaluation should be 
carried out according standard protocol. 
There are a few numbers of toxicity evaluation guidelines such as Food and 
Drug Administration (FDA) guidelines for food and colour additives toxicity level 
testing (Rulis and Levitt, 2008); European Union (EU) guidelines to examine 
industrial chemical toxicity stage (Ambachtsheer, Kron, Liroff, Little, and Massey, 
2007) and Organization for Economic Co-operation and Development (OECD) 
guidelines for evaluation of chemicals and plant extract toxicity intensities (Jaijoy, 
Soonthornchareon, Lertprasertsuke, Panthong, and Sireeatawong, 2010).   
Here in, OECD guidelines 423 (adopted: 2001) was used for the evaluation of 
acute oral toxicity evaluation of SMCM seed extract. The OECD 423 guideline is 
 
 
23
based on acute toxic class method where the toxicity evaluation is based on the 
stepwise dosing procedure using three animals of a single sex. This method is 
reproducible which uses a few animals only and able to rank toxicity of the test 
substance. In principle, the OECD guideline 423 is not intended to calculate precise 
LD50, but does allow for the determination of defined exposure ranges where 
lethality is expected ("OECD guidelines for testing of chemicals 423," 2001). 
2.5 Antimicrobial activity  
Infectious diseases are the leading cause of deaths world-wide. The clinical 
efficacy of many existing antibiotics is being threatened by the emergence of 
multidrug-resistant pathogens (Bandow et al., 2003) and currently it has become a 
crucial global concern (Westh et al., 2004; Ghalem et al., 2009). Human fungal 
infections have increased at an alarming rate in the last 20 years, mainly among 
immune-compromised individuals (Perea and Patterson, 2002; Scorzoni et al., 2007). 
New data indicate that the relative proportion of organisms causing nosocomial 
bloodstream infections has increased over the last decade (Scorzoni et al., 2007). 
Now Candida species is being firmly established as one of the most frequent agents 
among nosocomial bloodstream infections. Candidemia normally will lead to high 
mortality and also extends the length of hospitalization of a person and increases the 
costs of medical care. Candida species usually spread widely as they reside on 
plants, alimentary tracts of mammals and as also on human mucocutaneous 
membranes (Goncalves et al., 2006; Scorzoni et al., 2007). In the human 
gastrointestinal tract, around 50-70% of total yeast isolates were identified as 
Candida albicans. A number of antifungal drugs, such as polyene macrolides 
(Amphotericin B) and azoles (Itraconazole and Fluconazole) are currently used in 
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antifungal therapies. However, these antifungal agents endure a number of 
restrictions that can render their use complicated. For an example, Amphotericin B is 
associated with dose-limiting nephrotoxicity, while flucytosine and azoles showed 
resistant due to the rapid development among pathogenic strains, drug-drug 
interactions among the antifungal agents and fungi-static mode of action. As such the 
search of an alternative antifungal with broad fungicidal spectrum of action, and with 
fewer dose-limiting side effects (Graybill, 1996; Maertens and Brogaerts, 2000; 
Scorzoni et al., 2007) are of importance. Herbal medicines have been proven to be an 
excellent source of drugs, and this could serve in search of novel compounds with 
potential antifungal activity.   
Antifungal and antibacterial properties have been reported more frequently in 
a wide range of plant extracts in an attempt to discover new bioactive drugs that 
could resolve the infectious disease problems (Ali et al., 2001; Ho et al., 2001; 
Osibote et al., 2010). Countless infectious diseases have been known to be treated 
with herbal remedies throughout the history of mankind. At present, a number of 
drugs to treat bacterial and other infections are being isolated from natural sources 
including ethnomedicinal plants (Coe and Anderson, 1996). In accordance to WHO 
report, 20 000 plant species are presently in use for medicinal purposes (Scorzoni et 
al., 2007). Natural products, either as pure compounds or as standardized plant 
extracts, provide unlimited opportunities for new drug development. For example, 
the root crude extract of Garcinia atroviridis (asam gelugor) predominantly 
exhibited antibacterial activity with strongest inhibition against the test bacteria at a 
minimum inhibitory dose (MID) of 15.6 µg/disc (Mackeen et al., 2000). The 
essential oil of Satureja cuneifolia (used to produce essential oil and aromatic water) 
exhibited antimicrobial activity against selected food borne and spoilage bacteria 
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(Oke et al., 2009). Du et al. (2003) reported that, two novel antifungal activity 
triterpene saponins were isolated from aerial parts of a Tibetan herbal medicine 
Clematis tangutica. Recent finding stated that, orange essential oil was the most 
effective against Aspergillus niger, mandarin essential oil was most effective at 
reducing growth of Aspergillus flavus while grape fruit was the best inhibitor of 
Penicilium chrysogenum and Penicillium cerrucosum (Viuda-Martos et al., 2008). 
There is a continuous and urgent need to discover new antifungal and antibacterial 
compounds with diverse chemical structures and novel mechanisms of action for new 
and re-emerging infectious diseases (Rojas et al., 2003; Kage et al., 2009).  
2.5.1 Antimicrobial sensitivity test 
Antimicrobial activity of plants can be detected by observing the growth 
response of microorganisms towards the plants extracts/fractions/pure compound. 
This antimicrobial sensitivity test is used to establish the degree and spectrum of in 
vitro activity of a new antimicrobial drug. At present, the available methods for 
antimicrobial screening are such as agar diffusion, broth dilution and bioautographic 
techniques.  
2.5.2 Agar-based disc diffusion Assay 
Agar-based disc diffusion assay is effective because of its simplicity and low 
cost. In the diffusion technique, the organism under investigation is exposed to a 
reservoir-containing drug (plant extract) to be tested by an impregnated disc and the 
diameter (mm) of the zone around the reservoir (inhibition diameter) is measured 
(Figure 2.6). In order to lower the detection limit, the inoculated system is kept at 
low temperature during several hours before incubation, which favors the diffusion 
